SecBot SecBot
Biotech Drug Report Generated Aug 1, 2026

ONPATTRO

ALNY·ALNYLAM PHARMACEUTICALS, INC.
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved (marketed); Phase 3 (APOLLO-B) completed
Time to market
Already approved and marketed, FDA approval recorded 2018-08-10; no new indication approval pending in local FDA records.
Why 3/10
No Onpattro-specific hard, dated catalyst exists in the next ~12 months, its FDA approval (2018-08-10) is long past and its Phase 3 APOLLO-B cardiomyopathy trial is completed with no pending regulatory decision on record, so as an approved legacy drug it is capped at 3-5 and scores 3 because it is a minor, shrinking part of a multi-program company (ALNY's recent FDA catalysts concern other drugs, e.g. the cemdisiran NDA filed 2026-04-30).
Actionable Insight NEUTRAL

Do not position in ALNY for an ONPATTRO-specific catalyst, there isn't one on the horizon; treat ONPATTRO as a slowly amortizing cash-flow asset whose quarterly revenue lines (Q2 2026 10-Q filed 2026-07-30) are worth watching inside ALNY's earnings for the pace of patient transition to newer franchise drugs. ALNY's mean analyst target of ~$427.61 (observed 2026-07-31) implies the market values the pipeline, not this legacy product, so any trade thesis should hinge on the rest of the portfolio (e.g., cemdisiran) rather than ONPATTRO.

Price Chart

Loading chart...

Executive Summary

ONPATTRO (patisiran) is Alnylam Pharmaceuticals' RNAi drug, whose FDA approval is recorded locally as an 2018-08-10 approval catalyst (the stock rose ~3.3% the day of that record, then gave back ~3.2% over five days). Its follow-on Phase 3 cardiomyopathy trial, APOLLO-B, has completed. As an already-approved, commercialized product with no pending regulatory decision, ONPATTRO is not a binary catalyst for ALNY; the stock's drivers today sit elsewhere in the pipeline.

How It Works

ONPATTRO is an RNA-interference (RNAi) medicine: a small engineered piece of genetic material that silences the liver gene making transthyretin, the protein that misfolds and forms damaging amyloid deposits in nerves and the heart. It is given as an intravenous infusion, whereas Alnylam's newer franchise drugs use a more convenient subcutaneous injection.

Trial Status

Phase 3 APOLLO-B (NCT03997383, 360 patients, ATTR amyloidosis with cardiomyopathy, sponsor Alnylam) is COMPLETED with results posted; primary completion was 2022-06-20 (actual) and the trial completion date is recorded as 2025-12-24. The original hATTR polyneuropathy approval (2018) is on record as an FDA approval catalyst.

The Two-Sided Case

▲ Bull Case4
Approved and on the market: local FDA catalyst records show an FDA approval for ONPATTRO on 2018-08-10, giving Alnylam a durable commercial product and making it one of the earliest RNAi medicines to reach patients.
Phase 3 cardiomyopathy program completed: APOLLO-B (NCT03997383, 360 patients) is marked COMPLETED with results, preserving optionality around the ATTR-cardiomyopathy patient population that has become a major franchise battleground.
Parent-company support: ALNY carries 29 Buy/Strong-Buy ratings vs 9 Hold and 0 Sell (2026-07-01 consensus), with a mean analyst price target of $427.61 vs a ~$205.52 price (observed 2026-07-31), though this reflects the whole pipeline, not ONPATTRO alone.
ALNY is not a one-drug story: recent SEC-extracted catalysts for ALNY (cemdisiran NDA submission 2026-04-30) show the company has other shots on goal if ONPATTRO sales fade.
▼ Bear Case4
No upcoming binary: ONPATTRO has no pending PDUFA/pivotal readout in the next ~12 months, the approval binary passed in 2018, so the drug itself offers little catalyst-driven upside; per the impact rubric an approved drug with no pending decision caps at 5 and this legacy product scores 3.
Legacy-product risk: ONPATTRO is an older IV-infusion RNAi in a franchise Alnylam has since moved beyond (its recent FDA catalyst filings concern other drugs), raising internal-cannibalization and revenue-decline risk that this session's local data cannot quantify.
Cardiomyopathy path is not confirmed: APOLLO-B completed, but no FDA action or new approval for ONPATTRO in cardiomyopathy appears in local FDA/catalyst records, a label-expansion win cannot be assumed.
Stock-level caution: ALNY fell from the low-$320s (FTD reference price $323.50 on 2026-07-09) to ~$205.52 by 2026-07-31, with daily FINRA short-volume flow running ~55-69% of off-exchange volume in July and short interest ~4.32% of estimated shares outstanding (settlement 2026-07-15), a weak tape that would punish any disappointment in the commercial franchise.

Upcoming Catalysts

  • None scheduled for ONPATTRO itself in the next ~12 months.
  • Company-level watch items: Q2 2026 earnings were released 2026-07-30 (10-Q/8-K filed), check commentary on ONPATTRO/ATTR franchise revenue; cemdisiran NDA (filed 2026-04-30 for generalized myasthenia gravis) has an as-yet-unrecorded FDA action date.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

ALNYLAM PHARMACEUTICALS, INC. 8-K ALNY ·Originating report

Sources · 4

Hover a chip for the title
1 sec.gov2 sec.gov3 sec.gov4 sec.gov